Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$651.80 USD
-2.24 (-0.34%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $650.60 -1.20 (-0.18%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
REGN 651.80 -2.24(-0.34%)
Will REGN be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for REGN
REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
Compared to Estimates, Regeneron (REGN) Q3 Earnings: A Look at Key Metrics
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates
Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
Other News for REGN
Insider Moves: Blackstone, Regeneron, Schwab, Celestica, Corning
REGN forms Upper Bollinger Band Walk on October 31
Director’s Bold Move: Regeneron Stock Sale Shakes Up the Market!
Investor Michael Burry Warns Of Market Bubble
Upper Bollinger Band Walk appears for REGN after 0.17% move